The assumption that probiotic supplementation passively improves gut health without altering what people eat may deserve a second look. If microbiome-modulating interventions can nudge food preferences or appetite through the gut-brain axis, this would add a meaningful—and underappreciated—layer of complexity to how we interpret probiotic trial outcomes and design dietary interventions for mood disorders.
This double-blind, placebo-controlled sub-study embedded within the ProBioHRV trial enrolled 53 participants—23 with major depression and 30 healthy controls—who received either a multi-strain probiotic or placebo twice daily for three months. Dietary intake was tracked at baseline and three subsequent time points using the Vienna Food Record. The most notable pattern was a significant three-way interaction (time × intervention × diagnosis) for vitamin D intake: healthy controls showed elevated vitamin D consumption after just one week of probiotic use, while individuals with major depression demonstrated a similar but delayed trend emerging around the three-month mark. Paradoxically, probiotic users exhibited lower dietary variety and diversity scores at multiple assessment points, and folic acid intake also showed diagnosis-dependent shifts.
These findings occupy an interesting but cautious space in the gut-brain literature. The gut-brain axis is an established bidirectional communication pathway involving vagal signaling, enteroendocrine hormones, and microbial metabolites such as short-chain fatty acids—all of which can plausibly influence appetite and food-seeking behavior. However, this pilot study's sample size of 53 is far too small to draw firm conclusions, and the effect sizes were generally modest, with several results failing to clear conventional significance thresholds. The reduction in dietary diversity associated with probiotic use is counterintuitive and warrants particular scrutiny, since dietary diversity is itself a cornerstone of microbiome health. Whether this reflects a genuine microbiome-mediated appetite shift or simple trial-related behavioral drift remains unclear. This is an incremental but hypothesis-generating contribution; replication in larger, adequately powered cohorts with objective dietary biomarkers is essential before any clinical interpretation is warranted.